- Home
- FDUS vs ATXS Comparison
FDUS vs ATXS Comparison
Compare FDUS & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDUS
- ATXS
- Stock Information
- Founded
- FDUS 2011
- ATXS 2008
- Country
- FDUS United States
- ATXS United States
- Employees
- FDUS N/A
- ATXS N/A
- Industry
- FDUS Finance/Investors Services
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- FDUS Finance
- ATXS Health Care
- Exchange
- FDUS Nasdaq
- ATXS Nasdaq
- Market Cap
- FDUS 693.6M
- ATXS 669.8M
- IPO Year
- FDUS 2011
- ATXS 2015
- Fundamental
- Price
- FDUS $20.97
- ATXS $9.65
- Analyst Decision
- FDUS Hold
- ATXS Strong Buy
- Analyst Count
- FDUS 1
- ATXS 5
- Target Price
- FDUS $22.00
- ATXS $25.60
- AVG Volume (30 Days)
- FDUS 235.4K
- ATXS 240.3K
- Earning Date
- FDUS 10-31-2024
- ATXS 11-13-2024
- Dividend Yield
- FDUS 10.01%
- ATXS N/A
- EPS Growth
- FDUS 26.64
- ATXS N/A
- EPS
- FDUS 2.78
- ATXS N/A
- Revenue
- FDUS $145,008,000.00
- ATXS N/A
- Revenue This Year
- FDUS $12.92
- ATXS N/A
- Revenue Next Year
- FDUS $1.80
- ATXS N/A
- P/E Ratio
- FDUS $7.55
- ATXS N/A
- Revenue Growth
- FDUS 19.57
- ATXS N/A
- 52 Week Low
- FDUS $18.41
- ATXS $4.43
- 52 Week High
- FDUS $21.00
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- FDUS 74.60
- ATXS 38.31
- Support Level
- FDUS $19.02
- ATXS $8.61
- Resistance Level
- FDUS $20.84
- ATXS $9.83
- Average True Range (ATR)
- FDUS 0.24
- ATXS 0.75
- MACD
- FDUS 0.10
- ATXS -0.19
- Stochastic Oscillator
- FDUS 98.49
- ATXS 26.94
About FDUS Fidus Investment Corporation
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investments is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.